CCL2 and diabetes mellitus: Altogether, these findings suggest that IL-10 signaling in adipose tissue may be required for normal suppression of insulin resistance, and nondiabetic plasma treatment of SVFs that stimulates IL-10 production could be used as a novel cell therapy strategy to decrease proinflammatory cytokine expressions in the adipose tissue and liver, reduce systemic CCL2 levels, and improve insulin resistance in diabetics.